Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: In vitro and in vivo studies

Cancer

Volumn 95, Issue 9, 2002, Pages 1911-1922

  Selleri, Carmine ^a   Maciejewski, Jaroslaw P ^b   Catalano, Lucio ^a   Ricci, Patrizia ^a   Andretta, Claudia ^a   Luciano, Luigiana ^a   Rotoli, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Fas ligand; Fas receptor; Hematopoietic progenitors; Immunosuppression; Interferon ; Myelodysplasia; Th1

Indexed keywords

CD34 ANTIGEN; CYCLOSPORIN; FAS ANTIBODY; FAS LIGAND; GAMMA INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERFERON PRODUCTION; MALE; MYELODYSPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA;

ADULT; AGED; ANEMIA, REFRACTORY; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; ANTIGENS, CD4; ANTIGENS, CD95; ANTIGENS, SURFACE; CELLS, CULTURED; CYCLOSPORINE; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 0036840455     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10915     Document Type: Article

References (62)

1. Raza A. Evolving concepts in myelodysplastic syndromes. Cancer Treat Res. 2001;108:1-24.
2. Parker JE, Mufti GJ. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol. 2001;73:416-428.
3. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies. Leukemia. 2000;14:2-8.
4. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96:3932-3938.
5. Shetty V, Hussaini S, Broady-Robinson L, et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: Apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood. 2000;96:1388-1392.
6. Barrett J, Saunthararajah Y, Molldrem JJ. Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000;37:15-29.
7. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: Evidence for an autoimmune process. Leuk Res. 2001;25:1075-1083.
8. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol. 1998;102:1314-1322.
9. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): New proposals. Br J Haematol. 1995;91:612-617.
10. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336:1365-1372.
11. Maciejewski JP, Hibbs JR, Anderson S, Katevas P, Young NS. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol. 1994;22:1102-1110.
12. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol. 2001;29:1270-1277.
13. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 1992;6:1268-1272.
14. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049-2054.
15. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: Effects on in vitro hemopoiesis. Blood. 2001;98:3058-3065.
16. Allampallam K, Shetty V, Hussaini S, et al. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res. 1999;19:5323-5328.
17. Mundle SD, Reza S, Ali A, et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett. 1999;140:201-207.
18. Mundle SD, Ali A, Cartlidge JD, et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol. 1999;60:36-47.
19. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103:176-188.
20. Gupta P, Niehans GA, LeRoy SC, et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia. 1999;13:44-53.
21. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia. 1998;12:486-492.
22. + cells of patients with aplastic anaemia. Br J Haematol. 1995;91:245-252.
23. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90:1009-1013.
24. Geary CG, Harrison CJ, Philpott NJ, Hows JM, Gordon-Smith EC, Marsh JC. Abnormal cytogenetic clones in patients with aplastic anaemia: Response to immunosuppressive therapy. Br J Haematol. 1999;104:271-274.
25. Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T cell receptor Vβ usage in aplastic anemia. J Clin Invest. 2001;108:765-773.
26. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997;79:1548-1551.
27. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99:699-705.
28. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;100:304-309.
29. Asano Y, Maeda M, Uchida N, et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol. 2001;80:634-638.
30. Catalano L, Selleri C, Califano C, et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica. 2000;85:133-138.
31. Shimamoto T, Iguchi T, Ando K, et al. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br J Haematol. 2001;114:358-361.
32. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;160:4298-4304.
33. O'Garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol. 2000;10,542-550.
34. + helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol. 2000;12:375-380.
35. + T cells in the pathogenesis of organ specific autoimmune diseases. Immunol Today. 1995;16:34-38.
36. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995;181:71-77.
37. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med. 1998;4:31-36.
38. Raza A, Qawi H, Lisak L, et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofioxacin with or without dexamethasone. Blood. 2000;95:1580-1587.
39. Stasi R, Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol. 2002;116:334-337.
40. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001;115:881-894.
41. + human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85:3183-3190.
42. Selleri C, Maciejewski JP, Pane F, et al. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood. 1998;92:981-989.
43. Parker JE, Mufti GJ. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk Lymphoma. 2000;40:1-24.
44. Goyal R, Qawi H, Ali I, et al. Biologic characteristics of patients with hypocellular myelodysplastic syndromes. Leuk Res. 1999;23:357-364.
45. + cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry. Leuk Res. 2000;24:163-174.
46. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood. 1996;88:1983-1991.
47. + cells. Leuk Lymphoma. 1996;22:43-51.
48. Sato T, Kim S, Selleri C, Young NS, Maciejewski JP. Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome. Leukemia. 1998;12:1187-1194.
49. McMullin MF, Buckley O, Magill MK, Irvine AE. Long-term bone marrow culture profiles in patients with myelodysplastic syndromes are not explicable by defective apoptosis. Leuk Res. 1998;22:735-740.
50. Aizawa S, Nakano M, Iwase O, et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res. 1999;23:239-246.
51. Alvi S, Shaher A, Shetty V, et al. Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes. Leuk Res. 2001;25:941-954.
52. Deeg HJ, Beckham C, Loken MR, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma. 2000;37:405-414.
53. Yoshida Y, Mufti GJ. Apoptosis and its significance in MDS: Controversies revisited. Leuk Res. 1999;23:777-785.
54. Lepelley P, Grardel N, Erny O, et al. Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk Lymphoma. 1998;30:307-312.
55. Claessens YE, Bouscary D, Dupont JM, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: Evidence for Fas-dependent apoptosis. Blood. 2002;99:1594-1601.
56. Saunthararajah Y, Molldrem JL, Rivera M, et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: Clinical and pathophysiological features. Br J Haematol. 2001;112:195-200.
57. Luther-Wyrsch A, Nissen C, Wodnar-Filipowicz A.Intracellular Fas ligand is elevated in T lymphocytes in severe aplastic anaemia. Br J Haematol. 2001;114:884-890.
58. Raza A, Mundle S, Shetty V, et al. A paradigm shift in myelodysplastic syndromes. Leukemia. 1996;10:1648-1652.
59. Selleri C, Maciejewski J, Sato T, Young NS. Interferon-7 constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood. 1996;87:4149-4157.
60. Sato T, Selleri C, Young NS, Maciejewski JP.Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3. Blood. 1997;90:4749-4758.
61. Willman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1 mapping to chromosome 5q31.1 in human leukemia and preleukemic myelodysplasia. Science. 1993;259:968-971.
62. Brunner T, Yoo NJ, LaFace D, Ware CF, Green DR. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Int Immunol. 1996;8:1017-1026.